Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$109.04 USD
-2.37 (-2.13%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $109.52 +0.48 (0.44%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$109.04 USD
-2.37 (-2.13%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $109.52 +0.48 (0.44%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
Zacks News
Jazz (JAZZ) Down 7.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Jazz Pharmaceuticals (JAZZ) a Profitable Value Stock?
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) stock may be a good choice for value-oriented investors right now from multiple angles.
Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate
by Zacks Equity Research
Jazz (JAZZ) acquires privately-held Cavion for a total consideration of $312.5 million including an upfront payment of $52.5 million and $260 million in potential clinical, regulatory and commercial milestones.
Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports encouraging second-quarter 2019 earnings and revenues and raises its sales guidance for 2019.
Jazz Pharmaceuticals (JAZZ) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of 13.45% and 5.08%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Bausch Health (BHC) in Q2 Earnings?
by Zacks Equity Research
Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q2 results on Aug 6.
Is a Beat in the Cards for Regeneron (REGN) Q2 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2019 results.
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Jazz (JAZZ) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Jazz (JAZZ) Acquires Early-Stage Precision Oncology Asset
by Zacks Equity Research
Jazz (JAZZ) acquired Redx Pharma's early stage pan-RAF inhibitor program for developing potential treatment for cancer with RAF and RAS mutations.
ETF & Stock Winners of Longest US Economic Expansion
by Sanghamitra Saha
The U.S. economy has stepped into the 11th year of the expansion, exhibiting the longest expansion in history. These winning ETFs and stocks will rally further.
JAZZ or PCRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
JAZZ vs. PCRX: Which Stock Is the Better Value Option?
Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status
by Zacks Equity Research
Jazz Pharmaceuticals' (JAZZ) recently approved sleep drug, Sunosi, receives schedule IV designation under controlled substance list from the Drug Enforcement Agency.
Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Is Jazz (JAZZ) Down 7.3% Since Last Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
JAZZ or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Zacks.com featured highlights include: Gilead, Jazz, Amdocs, Arch Capital and Legg Mason
by Zacks Equity Research
Zacks.com featured highlights include: Gilead, Jazz, Amdocs, Arch Capital and Legg Mason
Is Jazz (JAZZ) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Jazz (JAZZ) is well positioned to outperform the market, as it exhibits above-average growth in financials.
5 Best PEG Stocks Suitable for GARP Investors
by Urmimala Biswas
While P/E alone only gives an idea of stocks that are trading at a discount, PEG, while adding the growth element to it, helps to identify stocks that have solid potential.
BioCryst Down Despite Hereditary Angioedema Study Meets Goal
by Zacks Equity Research
BioCryst's (BCRX) phase III study on BCX7353 for the prevention of hereditary angioedema attacks meets the primary endpoint for both doses (110mg/150 mg). Shares depreciate despite this upside.
JAZZ vs. PCRX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
JAZZ vs. PCRX: Which Stock Is the Better Value Option?
Is Jazz Pharmaceuticals (JAZZ) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 Small Drug Stocks Poised to Beat Q1 Earnings Estimates
by Zacks Equity Research
So far this earnings season, the going seems to be good for the medical sector. Let us take a glance at a few small drug companies, which are likely to beat on Q1 earnings.
3 Reasons Why Growth Investors Shouldn't Overlook Jazz (JAZZ)
by Zacks Equity Research
Jazz (JAZZ) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports encouraging first-quarter 2019 earnings and revenues and maintains its guidance for 2019.